ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients. - Wikidata - awgldk - TriplyDB

ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients.

ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients.

http://www.wikidata.org/entity/Q37194027

about

Circulating Tumor DNA as Biomarkers for Cancer Detection.Analysis of Paired Primary-Metastatic Hormone-Receptor Positive Breast Tumors (HRPBC) Uncovers Potential Novel Drivers of Hormonal Resistance Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor Prognostic role of PIK3CA mutations of cell-free DNA in early-stage triple negative breast cancer.Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients.Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant.Metastatic Breast Cancer With ESR1 Mutation: Clinical Management Considerations From the Molecular and Precision Medicine (MAP) Tumor Board at Massachusetts General Hospital ERα-XPO1 Cross Talk Controls Tamoxifen Sensitivity in Tumors by Altering ERK5 Cellular Localization.Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients.Clinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer Detection fidelity of AR mutations in plasma derived cell-free DNA Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2- advanced breast cancer: results from BOLERO-2.Adamantyl Antiestrogens with Novel Side Chains Reveal a Spectrum of Activities in Suppressing Estrogen Receptor Mediated Activities in Breast Cancer Cells.Comparison of ESR1 Mutations in Tumor Tissue and Matched Plasma Samples from Metastatic Breast Cancer Patients.Cell-free circulating tumour DNA as a liquid biopsy in breast cancer.Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients.Catalog of genetic progression of human cancers: breast cancer.Pathologic diagnosis of breast cancer patients: evolution of the traditional clinical-pathologic paradigm toward "precision" cancer therapy.Estrogen receptors in breast and bone: from virtue of remodeling to vileness of metastasis.Liquid biopsy: unlocking the potentials of cell-free DNA.Platelet RNA signatures for the detection of cancer.Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistance.Highly personalized detection of minimal Ewing sarcoma disease burden from plasma tumor DNA.Detection of ESR1 mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole.Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients.Cell-Free DNA in Oncology: Gearing up for Clinic.Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients.Mutational profiles of breast cancer metastases from a rapid autopsy series reveal multiple evolutionary trajectories.Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer.Comprehensive mutation and copy number profiling in archived circulating breast cancer tumor cells documents heterogeneous resistance mechanisms.Structurally Novel Antiestrogens Elicit Differential Responses from Constitutively Active Mutant Estrogen Receptors in Breast Cancer Cells and Tumors.Liquid Biopsy in Clinical Management of Breast, Lung, and Colorectal Cancer.Clinically Observed Estrogen Receptor Alpha Mutations within the Ligand-Binding Domain Confer Distinguishable Phenotypes.New Strategies in Metastatic Hormone Receptor-Positive Breast Cancer: Searching for Biomarkers to Tailor Endocrine and Other Targeted Therapies.Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer.High-sensitivity assay for monitoring ESR1 mutations in circulating cell-free DNA of breast cancer patients receiving endocrine therapy.Precision Medicine in Hormone Receptor-Positive Breast Cancer.Biotinylated amplicon sequencing: A method for preserving DNA samples of limited quantity Unraveling the clinicopathological features driving the emergence of mutations in metastatic breast cancer

P2860

Q33632125-53D83385-1802-422B-B2DD-D73A2D5C1B98 Q36022154-B59B511F-ECA0-48C7-8C85-3B7F48E86691 Q36179080-31A59D1A-50C9-4F8E-9FB3-BB9B2F1A3A5E Q36467458-A3851B2D-F3A6-49BE-85ED-5C8B9BC83725 Q36642923-AF080939-A204-4549-BC99-BE09A1159647 Q36907216-28014169-6689-4E67-8F75-A7065682D8D6 Q37242366-0A20827F-4913-4111-AA97-BB403B7BC94C Q37302065-A7768485-CFE1-4E00-9F64-8EC46AB15C29 Q37362696-0EF14905-ACF5-4362-B3DE-A1B0FEF183D7 Q37699590-08EEFCE1-9504-41A6-BC92-94E97D462AC1 Q37716596-8DD5EC5E-0412-4640-A4D2-C9DC65BB5975 Q38376017-011D6285-A7C0-4A26-BF4D-9D0DC530D54E Q38430208-E36FDA07-CF9A-4813-9914-11E4856676CB Q38640496-7F86645F-C544-4721-9921-6754B6294BC5 Q38699764-48984E82-5E9C-45EF-8915-70DA8E0DE0AF Q38717500-AE839FC0-AEC7-4D15-8958-48E94AFE2D95 Q38764251-EBBEE782-EC1F-4CA7-BDCC-86EF39C27B5F Q39187437-566F8E30-FCD9-48F1-B038-BEF8FB81E0CB Q39214999-49C6681C-2EEF-4B07-8A3A-B781E3E9F2F5 Q39279845-BB3C1EE1-E0D3-4D35-978D-7F24A0F2B5EC Q39417299-1FD00815-6F7E-41C2-9B2B-DB790464D5AB Q39767266-5560C111-AE5B-43FB-B086-2B4C044B16A2 Q40385437-90CF13CF-0AC4-4693-979A-02EC806B77F2 Q42084238-2F6C11A0-F571-4137-B007-31A7128200FC Q47127824-F722CAB0-B57A-4EBD-8690-F810BD34F2E0 Q47142145-7429063B-8464-4ABC-BBC5-37654C643110 Q47163200-87028BE3-4606-48DD-A0BC-BF9C6570EDC5 Q47230763-D2F310DE-EED7-418F-A60F-18C668FB4E69 Q47628875-84F705CB-EFBC-40C2-ACD3-867C54B76A37 Q47682423-505241B1-747A-4D9F-BDA3-ABE548E907D0 Q47807006-76D72FE1-EE48-4F7F-8745-AF58E16416AD Q49740946-AB459865-95E4-45CD-A5D5-6F8E7644C8DB Q50147171-B63358CE-BA33-4124-9252-6E825EBC7D63 Q52942118-BFDF3416-E329-43C2-A292-76B63CDB842B Q53146760-49EA1E8F-4CBB-44E7-BF39-588806E7B5FF Q53702674-E271F3BF-29CA-43A3-809E-C598004969BD Q55379220-6DCB7704-C1AB-4CC4-94CD-6A5274CABD90 Q58792941-CA233953-AA5E-4739-AFCC-39D3D8096A14 Q58803565-EAB0937C-1729-43B1-94E7-6B2AFC7EAA17

P2860

ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients.

http://www.wikidata.org/entity/Q37194027

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 10 August 2015

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients.

@en

ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients.

@nl

type

label

ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients.

@en

ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients.

@nl

prefLabel

ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients.

@en

ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients.

@nl

P1433

Q37194027-F27F6EF4-DCD0-4608-A245-87733771FA1B

P1476

Q37194027-80223818-FEB7-45A8-9A8E-3167AC79818F

P2093

Q37194027-04C550AE-7E50-4477-AF36-36C7780249F6

Q37194027-0C94ACFC-FBCC-4E3A-BCBC-192E8206E820

Q37194027-10E6870D-3A07-4D01-8AEF-5ECCBADA5A3B

Q37194027-1AD610AD-A0EB-4DFA-B05C-092A6D3B2C34

Q37194027-1E7F3C81-15AA-47B2-B237-99B7EA07D98C

Q37194027-1FB4FE37-E7A0-43EE-B177-02F1D192A09E

Q37194027-3CADF4EB-533A-40B2-8A78-209DC8A2EA1D

Q37194027-3D7A5525-6D56-4DEE-BDC2-6312098CA535

Q37194027-5BE99651-C103-4C65-8C01-CF1A2C6D9738

Q37194027-6906C389-215D-447A-BF61-9FFD7D07D640

P2860

Q37194027-04A9D8A2-2737-48A9-8712-5C79C75AB5E2

Q37194027-06AD8C6D-3214-4B8C-9F0C-D604404F2E8E

Q37194027-14B28CCE-041E-47F0-9BD2-A82BA2D9A3DF

Q37194027-1CA8EEE1-7A03-4A3D-9035-5188EA8D0EB3

Q37194027-1FAD37E1-9AEF-4E7C-8FC7-9E8B8CE6428E

Q37194027-3B9A20E0-97DB-4F17-9617-04F18F716DCC

Q37194027-401D37D8-E65E-4D99-9BCD-0522C9100D9F

Q37194027-4148FCD3-4F8D-481D-922B-360CF0768D34

Q37194027-531939CF-75DB-419A-9CDE-661057AFB03E

Q37194027-59D8E884-7B55-414E-B665-AA67B39F21E8

P304

Q37194027-61F7595F-81B7-4BF1-A092-4707EA077D88

P31

Q37194027-04BC0A8C-7FC0-498F-8DB5-BE5FA86B7716

P356

Q37194027-6A148AC9-1A4F-4984-A8E4-8642E4853B0C

P407

Q37194027-F2BC22F6-889D-4192-BBD4-CAC677BD1B41

P433

Q37194027-6A70252B-6C13-47B3-98E2-DC1A8EC5C2BC

P478

Q37194027-B617EB54-0737-471B-A69D-C0308B62DC5C

P50

Q37194027-124EAE51-7661-4545-9F11-3916FB749C91

Q37194027-15506134-6BD6-4460-B5CF-CFE87E0E9087

Q37194027-5256C125-41F5-4E33-A56E-EB551B0965E0

Q37194027-C41CAA0E-A5E1-4E4A-AB6F-7911A7FC7581

P577

Q37194027-187CB945-7C7E-40AB-8E3A-CA3CE02423D3

P698

Q37194027-480F8510-1FBE-4952-B579-0CFAC18A3D36

P932

Q37194027-030D5F89-3FE8-43EC-9ED4-A03A60D6D3DC

P356

1078-0432.CCR-15-0943

P1433

Clinical Cancer Research

P1476

ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients.

@en

P2093

Anne Schott

http://www.w3.org/2001/XMLSchema#string

Arielle Medford

http://www.w3.org/2001/XMLSchema#string

Arul M Chinnaiyan

http://www.w3.org/2001/XMLSchema#string

Ben Ho Park

http://www.w3.org/2001/XMLSchema#string

Berry Button

http://www.w3.org/2001/XMLSchema#string

Bracha Erlanger

http://www.w3.org/2001/XMLSchema#string

Christina Gersch

http://www.w3.org/2001/XMLSchema#string

Dan Robinson

http://www.w3.org/2001/XMLSchema#string

Daniel F Hayes

http://www.w3.org/2001/XMLSchema#string

Daniel J Zabransky

http://www.w3.org/2001/XMLSchema#string

P2860

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts

Activating ESR1 mutations in hormone-resistant metastatic breast cancer.

ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

Development of personalized tumor biomarkers using massively parallel sequencing

Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing

Circulating mutant DNA to assess tumor dynamics

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

P304

993-999

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-15-0943

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

Costanza Paoletti

Kelly Kyker-Snowman

Sarah Croessmann

P577

2015-08-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26261103

http://www.w3.org/2001/XMLSchema#string

P932

4993201

http://www.w3.org/2001/XMLSchema#string